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Abstract: Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone
acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC)
demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity
have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes
between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary
endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall
survival (OS). A total of five trials on 553 patients were included in this study. Each of the included
studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy
mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS
and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23–0.60) and 0.64 (p = 0.10; 95% CIs,
0.37–1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA
compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35–0.92) and
0.86 (p = 0.39; 95% CIs, 0.61–1.21), respectively. The current meta-analysis revealed that ABI-ENZA
had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore,
large-scale randomized trials may be needed.
Keywords: metastatic castration-resistant prostate cancer; abiraterone acetate; enzalutamide;
sequential therapy; systemic review; meta-analysis
1. Introduction
Prostate cancer (PC) is the most common type of newly diagnosed malignancy in men, accounting
for nearly 30% of all diagnosed cancers in men [1]. The initial treatment of patients with advanced
PC typically includes hormonal therapy along with medical or surgical castration (with or without
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antiandrogens) [2,3]. However, most metastatic PCs acquire resistance to initial hormonal therapy in
approximately 2–3 years and progress to castration-resistant prostate cancer (CRPC) [4]. Historically,
PC was considered moderately resistant to cytotoxic therapy [5]. A decade ago, docetaxel was the only
agent that improved the overall survival (OS) of metastatic CRPC (mCRPC) [6].
It has been well-documented that the androgen receptor (AR) axis is a key factor that drives
the disease progression of PC, even after the acquisition of a castration-resistant phenotype [7].
Consequently, two agents were developed as novel AR-axis-targeted (ARAT) agents—the androgen
biosynthesis inhibitor abiraterone acetate (ABI) and the second-generation antiandrogen enzalutamide
(ENZA)—and they improved survival outcomes in pivotal randomized clinical trials (RCTs) for both
docetaxel-naïve and treated patients with mCRPC [8–11]. In addition, these novel ARAT therapies
have better tolerability with respect to hematologic problems than docetaxel chemotherapy [12].
Although these two ARAT agents have similar clinical efficacy, no study has directly compared
the clinical outcomes of ABI and ENZA, and there exists no biomarker study aiding the individualized
selection of ARAT agents. In contrast, several studies have evaluated the outcomes of the second ARAT
agent after treatment failure of the first ARAT agent because their mechanism of action is different [13].
Sequential treatment of these ARAT agents demonstrated some positive effects, but cross-resistances
between ABI and ENZA that reduce activity has been suggested [14,15]. Recently, some studies
comparing the sequence of ABI to ENZA or ENZA to ABI have been published [16–20]. However,
they were retrospective series with a small number of patients and inconsistent results. Thus, a pooled
analysis of these studies was necessary. Therefore, we compared the clinical outcomes between the
treatment sequences of ABI–ENZA and ENZA–ABI through a systematic review and meta-analysis for
determining the appropriate treatment sequence of these therapies in patients with CRPC.
2. Materials and Methods
This systematic review was registered in PROSPERO (CRD42019142534).
2.1. Search Strategy
A literature search of all publications up to July 2019 was conducted using the Embase, PubMed,
and Cochrane library databases. In addition, a cross-reference search of eligible articles was performed
to detect studies that were not found in the computerized search. We used combinations of the following
MeSH terms and keywords such as “prostate,” “cancer,” “carcinoma,” “abiraterone,” “enzalutamide,”
“sequencing,” “sequential,” and relevant variants. The search included articles. Two authors (DYC
and JWK) independently reviewed the titles and abstracts based on the inclusion criteria and reviewed
the identified articles. In case of disagreement regarding the inclusion of an article, it was discussed
with the third author (KSC).
2.2. Inclusion Criteria and Study Eligibility
The eligibility of a study was evaluated based on the participants, intervention, comparator,
outcome, and study design approach and the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines. We defined participants and intervention as patients with
CRPC and those who underwent ABI–ENZA schedule from the beginning without any changes to the
schedule, respectively. The comparator was defined as patients who initially underwent ENZA–ABI
schedule. The primary endpoint was a combined progression-free survival (PFS). The secondary
endpoint was overall survival (OS). Combined PFS is defined as: (1) the time from the start date of
the first-line treatment with the first ARAT agent to disease progression following the second ARAT
agent; or (2) the sum of PFS1 and PFS2, representing PFS on the first- and second-line ARAT agents.
Disease progression was defined as prostate-specific antigen (PSA) and/or radiographic progression
examined using the Prostate Cancer Working Group (PCWG) 2 or 3 criteria [21,22]. OS was defined as
the time from the initiation of the first ARAT agent to death from any cause. There was no restriction
on research design, and both randomized controlled and nonrandomized observational studies were
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included. The exclusion criteria were as follows: (1) non-human study, (2) not written in English,
(3) conference and meeting abstracts, and (4) unable to extract outcome data. Conference and meeting
abstracts were excluded even if they fit the inclusion criteria for reducing publication bias.
2.3. Data Extraction
Two authors (DYC and JWK) independently reviewed the included articles and extracted data
at the trial level for each trial. Any discrepancy in extracted data was resolved through consensus.
Extracted data included details on study design, inclusion and exclusion criteria, whether participants
were randomized or nonrandomized, participant demographics and oncological characteristics, patient
treatment characteristics (ABI–ENZA or ENZA–ABI in patients with CRPC), outcomes measured
(combined PFS and OS), hazard ratios (HRs), 95% confidence intervals (CIs), and p-values.
2.4. Study Quality Assessments
After the final group of articles was agreed upon, two authors (DYC and JWK) independently
examined the quality. Quality evaluation of the nonrandomized studies was performed according to the
Newcastle–Ottawa Scale (NOS) [23]. The three major assessment categories of the NOS were selection,
comparability, and exposure. A study can be given a rating of up to 9 stars, and a final score of 6 stars
or more indicated a high quality. In addition, we assessed the quality of the generated evidence using
the Grading of Recommendations, Assessments, Developments, and Evaluation (GRADE) system.
GRADE is used to systematically approach the evaluation and strength of recommendations. It consists
of domains for methodology evaluation, accuracy of results, consistency of results, immediacy, and
risk of publication bias. Based on these five criteria, the quality of evidence was rated as belonging to
one of four levels (high, moderate, low, and very low) [24].
2.5. Statistical Analysis
The effects of ABI–ENZA compared with ENZA–ABI were measured using HRs. Log HR values
were obtained directly from the trials reporting HR point estimates and CIs, and the standard errors of
log HR were calculated using the published CIs [25]. In addition, PFS and OS analyses were performed
for both chemo-naïve patients alone and chemo-naïve and post-chemotherapy patients. Estimates
for the included studies were then combined using a random-effects model with inverse variance.
Pooled HRs with 95% CIs indicated the effects of ABI–ENZA or ENZA–ABI on OS and PFS. Chi-square
heterogeneity tests were used to test for statistical heterogeneity between trials. The I2 statistic was
calculated to measure discrepancies between clinical trials. A Cochran Q statistic p-value < 0.05 or an
I2 statistic > 50% was used to indicate the presence of statistically significant heterogeneity between
clinical trials [26]. Because fewer than 10 studies qualified for this review, funnel plots were not
used to assess small study effects. Sensitivity analysis was performed by evaluating the stability of
results by sequentially excluding each included study. We used Review Manager v.5.3 (2008; Nordic
Cochrane Center, Cochrane Collaboration, Copenhagen, Denmark) for performing the meta-analysis.
All p-values were two-sided, and except for the test of discrepancy, a p-value <0.05 was considered
statistically significant.
3. Results
3.1. Systematic Review Process
The results for the PRISMA flow diagram are presented in Figure 1. The initial database search
found 413 studies (137 in Embase, 238 in PubMed, and 38 in the Cochrane library). Among them, 53
studies remained after duplicates were removed. After reviewing the titles and abstracts, 23 articles
were excluded. Subsequently, analysis of the full-text articles was performed based on pre-established
inclusion criteria. Finally, five studies with a total of 553 patients were included. Information on the
included studies is presented in Table 1. All five studies were retrospective case–control studies [16–20].
Cancers 2020, 12, 8 4 of 12
Three were conducted in Japan [17,18,20], one in the United States [19], and one in Japan and the
United States [16]. Patients enrolled in the Maughan et al. study were also participants in the Terada
et al. study [16,19]. All trials enrolled patients diagnosed with CRPC who had undergone ARAT
treatment according to either ABI–ENZA or ENZA–ABI. In addition, the studies of Maughan et al.
and Mori et al. included both chemo-naïve and post-chemotherapy CRPC patients [17,19]. The other
studies were performed only in chemo-naïve CRPC patients [16,18,20].
3.2. Quality Assessment
The results of quality assessment using NOS for the included studies are shown in Table 2.
All studies received a score of 6 points. Overall, quality scores within subscales represented a relatively
high quality. However, in all studies, there was a bias for the selection of the control group cases.
Figure 1. Flowchart for the systematic review process and data acquisition.
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Table 1. Characteristics of the eligible studies.
Author(s)
(Year) Country Study Design Study Period Study Summary
1. Definition of Combined PFS
2. Definition of Disease Progression
3. Definition of OS
Schedule No. ofPatients
PFS
(Months,
IQR)
OS
(Months,
IQR)
Maughan et al.
(2017) USA
Retrospective Since 2011
Comparisons of oncologic outcomes between
ABI-to-ENZA and ENZA-to-ABI in both
chemo-naïve (n = 58) and post-chemotherapy
(n = 23) mCRPC patients
1. Sum of PFS1 and PFS2, representing PFSs on the first- and second-line ARAT agents
2. PSA and/or radiographic progression examined using the PCWG2 criteria
3. The time from initiation of the first ARAT agent to death from any cause
ABI-to-ENZA 65 19.53(15.5–22.3)
33.27
(25.4–NR)
ENZA-to-ABI 16 13.02(10.3–21.2)
29.98
(18.8–NR)
Mori et al.
(2017)
Japan Retrospective 2014–2016
Comparisons of oncologic outcomes between
ABI-to-ENZA and ENZA-to-ABI in both
chemo-naïve (n = 37) and post-chemotherapy
(n = 32) CRPC patients
1. Sum of PFS1 and PFS2, representing PFSs on the first- and second-line ARAT agents
2. PSA and/or radiographic progression examined using the PCWG2 criteria
3. The time from initiation of the first ARAT agent to death from any cause
ABI-to-ENZA 23 9(NR)
24
(NR)
ENZA-to-ABI 46 7(NR)
24
(NR)
Miyake et al.
(2017)
Japan Retrospective 2014–2016
Comparisons of oncologic outcomes between
ABI-to-ENZA and ENZA-to-ABI in
chemo-naïve mCRPC patients (n = 108)
1. Sum of PFS1 and PFS2, representing PFSs on the first- and second-line ARAT agents.
2. PSA progression examined using the PCWG2 criteria
3. The time from initiation of the first ARAT agent to death from any cause
ABI-to-ENZA 49 18.4(NR) NR
ENZA-to-ABI 59 12.8(NR) 22.1
Terada et al.
(2017)
USA and
Japan
Retrospective
Since 2011 in
USASince
2014 in Japan
Comparisons of oncologic outcomes between
ABI-to-ENZA and ENZA-to-ABI in
chemo-naïve mCRPC patients (n = 198)
1. From initiation of the ARAT agent until the time of progression on the subsequent
ARAT agent
2. PSA progression examined using the PCWG2 criteria
3. The time from initiation of the first ARAT agent to death from any cause
ABI-to-ENZA 113 455 days(385–495)
919 days
(761–NR)
ENZA-to-ABI 85 296 days(235–358)
899 days
(743–NR)
Matsubara
et al. (2018)
Japan Retrospective 2014–2016
Comparisons of oncologic outcomes between
ABI-to-ENZA and ENZA-to-ABI in
chemo-naïve mCRPC patients (n = 97)
1. From initiation of the ARAT agent until the time of progression on the subsequent
ARAT agent
2. PSA and/or radiographic progression examined using the PCWG2 or PCWG3 criteria
3. The time from initiation of the first ARAT agent to death from any cause
ABI-to-ENZA 50 11.1(8.00–14.05)
25.4
(19.8–31.1)
ENZA-to-ABI 47 9.04(6.84–11.24)
24.2
(20.2–28.2)
ABI, abiraterone acetate; ARAT, androgen receptor-axis targeted; ENZA, enzalutamide; mCRPC, metastatic castration resistance prostatic carcinoma; NA, not available; NR, not reached;
OS, overall survival; PCWG, Prostate Cancer Working Group; PFS, progression-free survival.
Table 2. Results of the quality assessment of nonrandomized studies by the Newcastle–Ottawa Scale.
Author(s) (Year)
Selection (4) Comparability (2) Exposure (3)
Total Score
Adequate
Definition of
Cases
Representativeness Selection ofControls Definition of Controls
Control for Important
Factor or Additional
Factor
Ascertainment of
Exposure
Same Method of
Ascertainment for
Cases and Controls
Non-Response Rate
Maughan et al. (2017) 1 1 0 0 2 1 1 0 6
Mori et al. (2017) 1 1 0 0 2 1 1 0 6
Miyake et al. (2017) 1 1 0 0 2 1 1 0 6
Terada et al. (2017) 1 1 0 0 2 1 1 0 6
Matsubara et al. (2018) 1 1 0 0 2 1 1 0 6
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3.3. Progression-Free Survival
A. Both chemo-naïve and post-chemotherapy CRPC patients:
In two studies that included both chemo-naïve and post-chemotherapy CRPC patients,
meta-analysis for PFS revealed an overall adjusted HR of 0.37 for ABI–ENZA compared with ENZA–ABI
(p < 0.0001; 95% CIs, 0.23–0.60). No heterogeneity was identified across studies (Cochran Q statistic,
p = 0.93; I2 statistic, 0%) (Figure 2a).
Figure 2. Forest plots for progression-free survival in studies including both chemo-naïve and
post-chemotherapy castration-resistant prostate cancer (CRPC) patients (A) and chemo-naïve CRPC
patients only (B).
B. Chemo-naïve CRPC patients only:
In three studies with chemo-naïve CRPC patients only, meta-analysis for PFS demonstrated an
overall adjusted HR of 0.57 for ABI–ENZA compared with ENZA–ABI (p = 0.02; 95% CIs, 0.35–0.92).
There was a statistically significant heterogeneity across studies (Cochran Q statistic, p = 0.02; I2 statistic,
74%) (Figure 2b).
3.4. Overall Survival
3.4.1. Both Chemo-Naïve and Post-Chemotherapy CRPC Patients:
In two studies that included both chemo-naïve and post-chemotherapy CRPC patients, there was
no significant difference in OS between ABI–ENZA and ENZA–ABI groups (adjusted HR, 0.64; 95%
CIs, 0.37–1.10; p = 0.10). No heterogeneity was identified across studies (Cochran Q statistic, p = 0.58;
I2 statistic, 0%) (Figure 3a).
3.4.2. Chemo-Naïve CRPC Patients:
In three studies with chemo-naïve CRPC patients only, there was no significant difference in
OS between ABI–ENZA and ENZA–ABI groups (adjusted HR, 0.86; 95% CIs, 0.61–1.21; p = 0.39).
No heterogeneity was identified across studies (Cochran Q statistic, p = 0.89; I2 statistic, 0%) (Figure 3b).
3.5. The Quality of Evidence using the GRADE
The assessment of the quality of evidence of each comparison using the GRADE approach is
shown in Table 3. Certainty was “low” in 1 comparison, and “very low” in the others.
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Table 3. Results of the GRADE quality assessment of direct evidence of each comparison.
Certainty Assessment Number of Patients Effect
Certainty Importance
Number of Studies Study Design Risk of Bias Inconsistency Indirectness Imprecision Other Considerations ABI-ENZA ENZA-ABI Relative (95% CI)
Progression-Free Survival of both Chemo-Naïve and Post-Chemotherapy CRPC Patients
2 retrospectiveobservational studies not serious not serious not serious Serious
a large effect b 88 62
HR 0.37
(0.23–0.60) Low critical
Overall Survival of both Chemo-Naïve and Post-Chemotherapy CRPC Patients
2 retrospectiveobservational studies not serious not serious not serious Serious
a,d none 88 62 HR 0.64(0.37–1.10) Very low important
Progression-Free Survival of Chemo-Naïve CRPC Patients
3 retrospectiveobservational studies not serious Serious
c not serious not serious none 212 191 HR 0.57(0.35–0.92) Very low important
Overall Survival of Chemo-Naïve CRPC Patients
3 retrospectiveobservational studies not serious not serious not serious Serious
d none 212 191 HR 0.86(0.61–1.21) Very low important
ABI, abiraterone acetate; CRPC, castration resistance prostatic carcinoma; ENZA, enzalutamide; HR, hazard ratio; OS, overall survival; PFS, progression-free survival. a Total number of
participants is small. b There is a large magnitude of effect. c Significant heterogeneity is observed. d The upper and lower limits of 95% CI include both meaningful benefit and harm.
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Figure 3. Forest plots for overall survival in studies including both chemo-naïve and post-chemotherapy
CRPC patients (A) and chemo-naïve CRPC patients only (B).
4. Discussion
Since 2010, five novel agents—including ABI, ENZA, sipuleucel-T, radium-223,
andcabazitaxel—have been approved for patients with CRPC. Although the survival benefits of
these agents have been established through phase 3 trials, no evidence exists regarding their clinical
activity when these drugs are given sequentially [15]. Thus, studies on the optimization of the treatment
sequence of these agents are necessary. During the last two decades, docetaxel chemotherapy has been
used in patients with mCRPC [6], but its use may be limited due to the modest survival benefit and
considerable side effects as a cytotoxic agent [27,28]. ABI and ENZA are ARAT agents with advantages
of oral administration, fewer adverse events than docetaxel chemotherapy, and improved oncologic
outcomes in patients with CRPC in both pre- and post-chemotherapy settings [8–11]. Therefore, ARAT
agents are currently chosen as the first agent in most patients with CRPC. In addition, a second ARAT
agent can be used subsequently instead of chemotherapy in case disease progression occurs after first
drug use. Several retrospective studies have analyzed the outcomes of sequential treatment with
ABI and ENZA in either order [29–36]. Several studies demonstrated a very low PSA response rate
(around 10%) [30–33], which suggests a cross-resistance between the two agents, thus raising some
doubt about the clinical benefit of a sequential therapy regimen with ABI and ENZA [37]. However,
other studies reported an acceptable PSA response rate (around 40%) [35,36], which suggests that
sequential treatment of ARAT agents can be beneficial in a certain group of patients. The optimal
sequence of these drugs has been questioned, and several comparative studies on this topic have been
published with inconsistent results [16–20].
The present study demonstrated better PFS outcomes of ABI–ENZA than ENZA–ABI, regardless
of the previous chemotherapy status but no difference in OS outcomes between the two groups,
suggesting that ABI–ENZA sequence can be helpful in maximizing the likelihood of achieving
acceptable PSA responses with both agents. Further, the results imply that this sequence exhibited
reduced cross-resistance, which can be a plausible explanation for the difference in PFS outcomes [19].
Two previous studies have compared the sequential treatment of ARAT agents [13,38]. Maines et al.
compared the cumulative monthly survival rates between ABI–ENZA (7 studies, 317 patients) and
ENZA–ABI (3 studies, 80 patients) [13] and suggested that ENZA–ABI led to a slightly longer OS than
ABI–ENZA. In addition, Zhang et al. analyzed differences in oncological outcomes between these two
sequences through indirect comparisons [38]. The median OS was 9.7 and 7.4 months and median
PFS was 3.2 and 2.9 months in ENZA–ABI and ABI–ENZA, respectively. The results of these two
studies are contrary to our findings, but there are significant differences between our study and their
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studies. First, our study predominantly comprised docetaxel-naïve CRPC patients (90%), whereas
their studies included patients with a history of docetaxel chemotherapy failure. Second, our study
was a meta-analysis that incorporated direct comparisons, whereas their results were drawn from
indirect comparisons. In addition, we calculated the estimate of pooled effect with adjusted HRs from
multivariate analysis, whereas they used unadjusted HRs from univariate analysis.
Chopra et al. performed indirect comparisons between ABI and ENZA in both pre-docetaxel and
post-docetaxel settings based on published phase 3 RCTs [39] and found that ENZA outperformed ABI
with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate but
not OS in both the pre- and post-docetaxel settings. The rate of adverse events of grade ≤3 was similar
between ABI and ENZA. Therefore, it might be more reasonable to choose ENZA than ABI when ARAT
agents are not used sequentially. However, for the sequential use of ARAT agents, the ABI–ENZA
sequence might be a better choice than the ENZA–ABI sequence, especially in docetaxel-naïve CRPC
patients, based on our findings. The lack of randomized head-to-head comparison data between
ABI and ENZA and between ABI–ENZA and ENZA–ABI makes it difficult to choose the optimal
first-line treatment either pre- or post-chemotherapy in patients with CRPC. An ongoing, prospective
RCT comparing the use of ABI–ENZA and ENZA–ABI (clinical trial information: NCT02125357) will
provide valuable information for optimal sequencing of ARAT agents. Apart from the oncologic
outcome, the use of ABI–ENZA may have the advantage of a lower cost of treatment than ENZA–ABI
in patients with mCRPC [40]. The duration of the first ARAT agent is generally longer than that of the
second drug due to cross-resistance; therefore, the ABI–ENZA sequence may reduce the burden of
pharmacy cost on patients compared to ENZA–ABI. However, this may vary depending on the health
insurance system of each country.
Another critical issue is whether to choose docetaxel chemotherapy or ARAT therapy first.
Recently, biomarker studies have been conducted to predict treatment response and prognosis. Among
these, androgen receptor-variant 7 (AR-V7) appears to be a promising molecular biomarker that
predicts the response to ARAT agents and taxane treatment [41,42]. AR-V7-positive patients showed
a lower response rate with ENZA or ABI than AR-V7-negative patients. Although the presence of
AR-V7 is not an absolute contraindication for ARAT agents, it may reduce the effectiveness of these
drugs. Taxane therapy is more efficacious than ARAT agents in AR-V7-positive patients. However,
the clinical outcomes did not seem to differ significantly on the basis of the type of therapy used in
AR-V7-negative patients [43]. In addition, several studies suggested that docetaxel chemotherapy
may produce resistance to AR [14,15]. Therefore, ARAT therapy may be an appropriate option in
chemo-naïve patients for adequate treatment responses, especially when the AR mutation status is
not identified.
There are some limitations to our study. First, all five studies included in our analysis were
retrospective studies, there was unavoidable bias such as nonrandomized treatment allocation,
unbalanced grouping, and non-standardized data collection. This is a major drawback of our study.
So, we provided the quality of evidence for the synthesized outcome through the GRADE approach.
As a result, the level of evidence was low or very low, owing to the nature of retrospectively designed
studies and small number patients. Thus careful interpretation is required, and large-scale randomized
studies are needed to verify this result. Second, studies by Maughan et al. and Mori et al. included
both chemo-naïve and post-chemotherapy patients. As mentioned above, the efficacy of ARAT drugs
can be limited in the post-chemotherapy setting. Third, there were some differences in the definition of
combined PFS and disease progression between the studies. Two studies evaluated disease progression
only with PSA, and some patients may have radiographic progression without PSA progression.
Finally, data on subsequent treatment after sequential therapy of ARAT agents were not collected;
therefore, their impact on the outcomes was not considered. Despite these limitations, our study is
valuable as the first meta-analysis that directly compares the oncologic outcomes between ABI–ENZA
and ENZA–ABI. We provide evidence that ABI–ENZA may be a better sequential ARAT treatment
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than ENZA–ABI in patients with mCRPC. This finding will be useful until more solid conclusions
through well-designed RCTs can be obtained.
5. Conclusions
In the present meta-analysis, a significant difference was identified in the oncological outcomes
between ABI–ENZA and ENZA–ABI in patients with mCRPC. ABI–ENZA had better PFS outcomes
than ENZA–ABI; however, there was no difference in OS outcomes. ABI–ENZA might be an optimal
strategy for sequential ARAT treatment in patients with mCRPC based on the currently available
evidence, but this level of evidence was low or very low. Therefore, the interpretation of this result
should be undertaken carefully, and large-scale randomized trials are needed to verify this result.
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